Evidence map›Paper›PMID 20616157›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2010

Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.

Brian S Decker, Michael B Kays, Mary Chambers, Michael A Kraus, Sharon M Moe, Kevin M Sowinski

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00596167 (Intradialytic Drug Removal by Short-daily Hemodialysis), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00596167 nacompletednot on this map

Intradialytic Drug Removal by Short-daily Hemodialysis

TypeinterventionalSponsorIndiana UniversityRan2007 to 2009Enrolled6ConditionsEnd Stage Renal Disease, InfectionArmsIntravenous antibiotics
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. The Nephrotoxicity of Vancomycin.Clinical pharmacology and therapeutics · 2017
    Review
  5. Review of vancomycin-induced renal toxicity: an update.Therapeutic advances in endocrinology and metabolism · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Brian S DeckerIndiana University School of Medicine, Indianapolis, IN, USA. bsdecker@iupui.edu
Michael B Kays
Mary Chambers
Michael A Kraus
Sharon M Moe
Kevin M Sowinski
Indiana University – Purdue University Indianapolis · USPediatric Nephrology of Alabama · USPurdue University West Lafayette · US

Funding

INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
Effect of different hemodialysis modalities on hepatic CYP450 metabolismK23DK084260 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DECKER, BRIAN SCOTT · 2010 to 2014
$872k
NCRR NIH HHS UL1 RR025761NCRR NIH HHS UL RR025761NIDDK NIH HHS K23 DK084260
6 · The paper itself

Abstract

BACKGROUND AND

objectivesShort daily hemodialysis (SDHD) is an alternative to thrice-weekly HD because of its putative physiologic benefits. The purpose of this study was to investigate the effect of SDHD on the pharmacokinetics and pharmacodynamics of vancomycin. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Six noninfected adults who had anuria and were treated with SDHD were studied and received four dialysis sessions over 4 days. After completion of the first SDHD, each patient received vancomycin 15 mg/kg by intravenous infusion. Blood samples were collected over the ensuing 3 days during each subsequent inter- and intradialytic period. Pharmacokinetic parameters were determined. Serum concentration-time profiles were simulated for four vancomycin regimens with maintenance doses administered after every other SDHD. Area under the serum-concentration time curve (AUC) from 0 to 48 hours, 48 to 96 hours, and 96 to 144 hours were calculated, and Monte Carlo simulations were performed to determine the probability of target attainment at an AUC/minimum inhibitory concentration (MIC) ratio ≥800 for each 48-hour AUC at MICs ranging from 0.5 to 2.0 μg/ml.

resultsMedian (range) systemic clearance was 7.2 ml/min (5.3 to 10.0 ml/min), and dialytic clearance was 104 ml/min (94 to 106 ml/min). The steady-state volume of distribution was 55.4 L (34.8 to 77.2 L). At MICs ≤1 μg/ml, probability of target attainment was >90% for each 48-hour AUC when vancomycin was administered as a 20-mg/kg loading dose followed by 10 mg/kg after every other SDHD.

conclusionsVancomycin pharmacokinetic parameters in SDHD are consistent with data from thrice-weekly HD. A loading dose of 20 mg/kg followed by 10 mg/kg after every other SDHD provides adequate exposure for pathogens with MICs ≤1 μg/ml.

Indexed as

AdultAnti-Bacterial AgentsAnuriaArea Under CurveComputer SimulationDrug Dosage CalculationsFemaleHumansIndianaInfusions, IntravenousMaleMetabolic Clearance RateMicrobial Sensitivity TestsMiddle AgedModels, BiologicalMonte Carlo MethodAnti-Bacterial AgentsVancomycin

Identifiers

PMID20616157
PMCPMC3001762
OpenAlexW2109279530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.